INFECTIOUS COMPLICATIONS IN LIVER TRANSPLANT RECIPIENTS ON TACROLIMUS Prospective Analysis of 88 Consecutive Liver Transplants

1994 ◽  
Vol 58 (7) ◽  
pp. 774-778 ◽  
Author(s):  
Nina Singh ◽  
Timothy Gayowski ◽  
Marilyn Wagener ◽  
Victor L. Yu
Keyword(s):  
Liver Transplant ◽  
Infectious Complications ◽  
Prospective Analysis ◽  
Transplant Recipients ◽  
Liver Transplants ◽  
Liver Transplant Recipients

scholarly journals Endoscopic Management of Biliary Complications following Liver Transplantation after Donation from Cardiac Death Donors

2012 ◽  
Vol 26 (9) ◽  
pp. 607-610 ◽  
Author(s):  
Kris P Croome ◽  
Vivian McAlister ◽  
Paul Adams ◽  
Paul Marotta ◽  
William Wall ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Transplant ◽  
Cardiac Death ◽  
Hepatic Duct ◽  
Biliary Complications ◽  
Endoscopic Management ◽  
Transplant Recipients ◽  
Biliary Strictures ◽  
Liver Transplants ◽  
Liver Transplant Recipients

BACKGROUND Previous studies have shown a higher incidence of biliary complications following donation after cardiac death (DCD) liver transplantation compared with donation after brain death (DBD) liver transplantation. The endoscopic management of ischemic type biliary strictures in patients who have undergone DCD liver transplants needs to be characterized further.METHODS: A retrospective institutional review of all patients who underwent DCD liver transplant from January 2006 to September 2011 was performed. These patients were compared with all patients who underwent DBD liver transplantation in the same time period. A descriptive analysis of all DCD patients who developed biliary complications and their subsequent endoscopic management was also performed.RESULTS: Of the 36 patients who received DCD liver transplants, 25% developed biliary complications compared with 13% of patients who received DBD liver transplants (P=0.062). All DCD allograft recipients who developed biliary complications became symptomatic within three months of transplantation. Ischemic type biliary strictures in DCD allograft recipients included disseminated biliary strictures in two patients, biliary strictures of the hepatic duct bifurcation in three patients and biliary strictures of the donor common hepatic duct in three patients.CONCLUSIONS: There was a trend toward increasing incidence of total biliary complications in recipients of DCD liver allografts compared with those receiving DBD livers, and the rate of diffuse ischemic cholangiopathy was significantly higher. Focal ischemic type biliary strictures can be treated effectively in DCD liver transplant recipients with favourable results. Diffuse ischemic type biliary strictures in DCD liver transplant recipients ultimately requires retransplantation.

scholarly journals Management of COVID-19 in Liver Transplant Recipients with Immunosuppressant Therapy: Experiences of an Iranian Transplant Registry

2020 ◽  
Author(s):  
Zahra Sheikhalipour ◽  
Touraj Asvadi kermani ◽  
Farzad Kakaei ◽  
Azizeh Farshbaf Khalili ◽  
Leila Vahedi
Keyword(s):  
Liver Transplantation ◽  
Liver Transplant ◽  
Organ Transplant ◽  
Immunosuppressive Drugs ◽  
Personal Hygiene ◽  
Transplant Recipients ◽  
Liver Transplants ◽  
Transplant Registry ◽  
Use Of Medical Services ◽  
Liver Transplant Recipients

Abstract Background: Following the pandemic of COVID-19 and the increased COVID-19 risk in transplant patient receptions, the authors assessed the prevalence, clinical course, and the outcome of the COVID-19 infection among liver transplant receptions. Methods: By designing and the use of researcher made questionnaire and the use of medical services, liver transplantation recipients under our center surveyed in terms of COVID-19 infection.Results: Seven patients infected with COVID-19 were identified from 265 liver transplantation recipients. The majority of patients were male and had COVID-19 despite being in-home quarantine. All patients received immunosuppressive drugs during infection with COVID-19 with no change in the routine immunosuppressive therapy. Among the identified patients, 5 recovered and 2 died. One of the dead patients, in addition to having a liver transplant, suffered brain cancer with metastasis to the lungs. Conclusion: It seems that the in liver transplants infected with COVID-19, the immunosuppressive drugs causes mild to moderate illness, and even recover from the disease.However, more evidence is needed to prove this hypothesis. It is also recommended that transplant recipients should be warned about personal hygiene and closely be monitored by organ transplant centers.

Biliary and urinary neopterin concentrations in monitoring liver-allograft recipients

1993 ◽  
Vol 39 (1) ◽  
pp. 45-47 ◽  
Author(s):  
A Hausen ◽  
C Aichberger ◽  
A Königsrainer ◽  
G Weiss ◽  
R Margreiter ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Cytomegalovirus Infection ◽  
Infectious Complications ◽  
Transplant Recipients ◽  
Liver Allograft ◽  
Post Transplant ◽  
Bile Fluid ◽  
Urinary Neopterin ◽  
Liver Transplant Recipients

Abstract Biliary neopterin concentrations were measured daily in nine liver-transplant recipients during the early post-transplant period (on average, 25 days). Concentrations increased strongly during rejection episodes and decreased quickly after successful antirejection therapy. Contrary to the changes of urinary neopterin, cytomegalovirus infection and hepatitis were not associated with an increase in biliary neopterin concentrations. Therefore, measurement of neopterin in bile fluid and in urine may aid in distinguishing rejection from infectious complications in liver-allograft recipients.

Prospective Analysis of Metabolic Parameters in the Detection of Diabetes and Metabolic Syndrome in Liver Transplant Recipients

2016 ◽  
Vol 14 (6) ◽  
pp. 305-310 ◽  
Author(s):  
Allon Kahn ◽  
Justin A. Reynolds ◽  
Harini A. Chakkera ◽  
Bashar A. Aqel ◽  
Thomas J. Byrne ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Transplant ◽  
Metabolic Parameters ◽  
Prospective Analysis ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

scholarly journals Procalcitonin as a prognostic marker for infectious complications in liver transplant recipients in an intensive care unit

2010 ◽  
Vol 16 (3) ◽  
pp. 402-410 ◽  
Author(s):  
Maartje A. J. van den Broek ◽  
Steven W. M. Olde Damink ◽  
Bjorn Winkens ◽  
Christoph E. Broelsch ◽  
Massimo Malagó ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Liver Transplant ◽  
Prognostic Marker ◽  
Infectious Complications ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

scholarly journals Procalcitonin, a Biomarker for Diagnosing and Differentiating Infection among Liver Transplant Recipients: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Wei Dong ◽  
Ding-yuan Wan ◽  
Xi Zhong ◽  
Xin-yao Luo ◽  
Yu-meng Wu ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Transplant ◽  
Likelihood Ratio ◽  
Positive Likelihood Ratio ◽  
Threshold Effect ◽  
Diagnostic Value ◽  
Infectious Complications ◽  
Cochrane Library ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

Abstract Background Infection has long been the major cause for death after liver transplantation. Diagnosing this deadly disease in time can be of great help to support the patients in intensive care units. However, tests like blood culture would take too much time to generate an outcome. Procalcitonin seems to be a promising biomarker in such clinical settings these days. To evaluate its diagnostic value as a biomarker in identifying and differentiating infectious complications in liver transplant recipients. Methods PUBMED, Scopus, Web of Science, Cochrane Library were searched for articles published from January 1990 to September 2019 without language limitation. Cohort or case-control study investigating the value of PCT in distinguishing postoperative infectious complications among liver transplant recipients were included, followed by measurement using QUADAS-2 tool to estimate the risk of bias of each study. Bivariate approach and random-effects model were performed to generate the pooled outcomes. Results 8 studies (studying 560 liver transplant recipients) from 6 populations were reviewed and included, one of which is later excluded due to huge heterogeneity it caused. No significant threshold effect was found, suggesting that heterogeneity returned by the I 2 was not due the various cutoff values. The pooled DOR was 18.65 (95%CI 9.85-35.31) and the area under HSROC was 0.857 ( θ =-0.024; β =-0.203). The positive likelihood ratio and negative likelihood ratio are 3.472 (95% 2.352-5.127) and 0.289 (95% 0.192-0.434). Conclusion Current articles suggest a reasonable diagnostic value for the procalcitonin test in identifying infectious complications among patients undergoing liver transplantation. However, the reason why no threshold effect was found remained explored.

Sign in / Sign up

Export Citation Format

Share Document